MRNA - Latest News

Moderna, Inc. (MRNA), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $20.01B. Beta to the broader market is 1.06.

The article list below shows the most recent MRNA headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent MRNA Headlines

3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally

fool.com - May 13, 2026

The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine mar

Moderna Recognized by TIME as One of the World's Most Impactful Companies

accessnewswire.com - May 12, 2026

CAMBRIDGE, MA / ACCESS Newswire / May 12, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked no.

Moderna, Inc. (MRNA) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - May 12, 2026

Moderna, Inc.

Moderna's AI Could Get a Hantavirus Vaccine Here Faster

pymnts.com - May 12, 2026

Drug development has always been a slow business. A single medicine can take 10 to 15 years and cost billions before it reaches a patient.

Hantavirus outbreak: these 3 stocks are poised to rip higher

invezz.com - May 11, 2026

The World Health Organization's recent report of a Hantavirus cluster aboard a cruise ship departing Argentina has refocused global market attention o

How News Affects MRNA Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track MRNA's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked MRNA news questions

What is the latest MRNA news headline?
The most recent MRNA headline (May 13, 2026) is "3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
How fresh is the MRNA news on this page?
News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
What MRNA news moves options pricing?
Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
How can I track unusual MRNA options activity related to news?
Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.